Melanoma Research Alliance: Special Opportunity Awards: MRA-Pfizer Established Investigator Partnership Award - LOI

Applications are solicited to evaluate the therapeutic potential of CDK4/6 inhibition in melanoma. Proposals evaluating biomarkers of response to CDK4/6 inhibition, interactions with dysregulated signaling pathways such as MAPK, combinatorial treatment regimens, and efficacy in treating or preventing resistance to agents targeting signaling pathways or immunologically relevant molecules, are encouraged. A letter of support from Pfizer is required at the time of application. All “letters of intent” for planned research proposals should be sent to Pfizer.
http://www.curemelanoma.org/research/request-for-proposals